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 2
ABSTRACT: 24 
 25 
Human La protein has been implicated to facilitate internal ribosome entry site (IRES) mediated 26 
translation of hepatitis C virus (HCV). Earlier, we have demonstrated that RNA recognition 27 
motif (RRM) encompassing 112-184 residues of La protein interacts with HCV-IRES near 28 
initiator AUG. A synthetic peptide LaR2C (24mer), derived from La-RRM (112-184), retained 29 
RNA binding ability, competes with the La protein binding to HCV IRES and inhibits 30 
translation. The peptide interferes with the assembly of 48S complexes resulting in the 31 
accumulation of pre-initiation complexes that are incompetent for the 60S ribosomal subunit 32 
joining. Here, NMR spectroscopy of the HCV-IRES bound peptide complex revealed putative 33 
contact points, mutations at which showed reduced RNA binding and translation inhibitory 34 
activity. The residues responsible for RNA recognition were found to form a turn in the RRM 35 
(112-184) structure. A 7-mer peptide comprising this turn showed significant translation 36 
inhibitory activity. The bound structure of the peptide inferred from transferred NOE 37 
experiments suggests it to be a ?-turn. This conformation is significantly different from that 38 
observed in free RRM (112-184) NMR structure suggesting paths towards a better stabilized 39 
mimetic. Interestingly, addition of hexa-arginine tag enabled the peptide to enter Huh7 cells and 40 
showed inhibition HCV-IRES function. More importantly, the peptide significantly inhibited 41 
replication of HCV monocistronic replicon. Elucidation of the structural determinant of the 42 
peptide provides basis for developing small peptidomimetic as potent anti-HCV therapeutics. 43 
 44 
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INTRODUCTION: 45 
The mechanism of internal initiation of translation of HCV RNA is unique and fundamentally 46 
different from the cap-dependent translation of host cell mRNAs and thus HCV-IRES offers a 47 
potential target for developing novel antiviral therapeutics (7). 48 
The ribosome assembly at the Hepatitis C virus IRES has been shown to be ‘prokaryotic 49 
like’ and requires minimal number of initiation factors (28). HCV IRES has been shown to be 50 
capable of binding directly to 40S ribosomal subunit with the help of the ribosomal protein S5 51 
(12, 21, and 32). Although, HCV IRES binds to the 40S ribosomal subunit specifically and 52 
stably even in the absence of any initiation factors, efficient translation requires some of the 53 
canonical initiation factors and non-canonical trans-acting factors, possibly to facilitate ribosome 54 
binding and to ensure proper positioning of the initiator AUG in the P site (15). Several cellular 55 
trans-acting factors have been reported to be critically required for HCV IRES mediated 56 
translation, which includes human La autoantigen (2, 7, 15 and 21).  57 
           Human La protein was originally identified in the sera from patients with systemic lupus 58 
erythematosus (SLE) and Sjögren syndrome (34). Earlier it was reported in the literature that La 59 
protein contains three RRMs, which were putatively located in between 1-100 (RRM1), 101-208 60 
(RRM2) and between 209-300 (RRM3) [14, 29]. However, according to the recent 61 
nomenclature, the first structured domain in human La is termed as the ‘La motif (16-75)’, 62 
followed by two RRMs, RRM1 (112-184) and RRM2 (230-300) (27, 35). Although, based on the 63 
structure determinations (from NMR and PX data) the precise boundary of the structured cores 64 
were found to be slightly different [La-motif (7-92), RRM1 (110-194), RRM2 (229-327)] but 65 
they largely encompasses the above regions (1, 20). 66 
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La gets associated with the 3' termini of many newly synthesized small RNAs made by RNA 67 
polymerase III as well as certain small RNAs synthesized by other RNA polymerases (24, 38).  68 
The N terminal 80aa residues termed as La motif and the adjacent RRM part has been shown to 69 
be required for high affinity binding with pol III transcripts, where the La motif helps in specific 70 
recognition for poly uridylate sequence (UUUOH) at the 3` end of the RNA. The C terminal RRM 71 
(230-300) has been shown to have a beta sheet comprising 5 strands and a long C terminal helix 72 
that binds to the putative RNA binding site (20). The central RRM (112-184) has been shown to 73 
possess a classical RRM-type fold containing four stranded beta sheet backed by two alpha 74 
helices.  It also has an additional beta-strand inserted between alpha 2 and beta 4. The helix alpha 75 
3 of RRM (112-184) is predominantly hydrophilic and protrudes away from the body of the 76 
domain. The beta sheet surface of the central RRM (112-184) contains 5 basic residues and no 77 
acidic residues, which makes it more basic and suitable for RNA interactions (1).   78 
 La protein has been shown to bind several viral and cellular IRES elements and 79 
influences their function. In fact it has been implicated as a molecular chaperone to facilitate 80 
IRES structure and translational competence (6).  La protein has been shown to enhance 81 
poliovirus IRES function and corrects its aberrant translation in reticulocyte lysate (25).  82 
Earlier we have demonstrated that La protein plays important role in mediating HCV IRES 83 
mediated translation. It interacts at GCAC motif near initiator AUG of HCV IRES, which might 84 
trigger some conformation alterations that facilitates formation of functional initiation complex 85 
and stimulate internal initiation of translation (29). It also seems to assists the binding of 86 
ribosomal protein S5 and probably plays a role in recruitment of 40S ribosomal subunit to HCV 87 
IRES (31). Recently, we have demonstrated that a 24-mer peptide (LaR2C) derived from the C-88 
terminus of the RRM (230-300) of La protein competes with the cellular La protein binding to 89 
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the HCV IRES and interferes with the functional initiation complex formation (30). It appears 90 
that LaR2C interferes with 48S ribosome complexes, rendering it incompetent for 60S joining 91 
during internal initiation of translation of HCV RNA (30).  92 
 Here we report, characterization of the structural and functional domain of the LaR2C 93 
peptide. Using NMR spectroscopy of the RNA bound peptide coupled with mutational analysis 94 
we have delineated the minimal sequences within the peptide required for binding and inhibition 95 
of HCV RNA translation. We have shown the presence of a unique ?-turn at the N terminus of 96 
the peptide which is more or less sufficient for its function. More importantly, we have 97 
demonstrated direct delivery of the arginine-tagged peptide inside the Huh 7 cells. The study 98 
constitutes the first report of a small anti-HCV peptide (7-mer) targeting HCV-IRES and 99 
provides the ‘proof of concept’ that a peptide comprising of minimal RNA binding domain can 100 
successfully inhibit HCV RNA translation and replication, which can be exploited as a target to 101 
design efficient and more potent antiviral therapeutics against HCV infection in near future. 102 
ACC
EPT
ED
 6
MATERIALS AND METHODS: 103 
NMR spectroscopy: 104 
Both peptide and RNA were dissolved in 20 mM potassium phosphate buffer, pH 7 containing 105 
0.1 M KCl and 10% D2O. All spectra of LaR2C were recorded in a 500 MHz DRX-500 (Bruker 106 
Biospin, Switzerland) at 27ºC, unless stated otherwise. TOCSY (mixing time 80ms) and NOESY 107 
(mixing time 400ms) spectra were recorded with solvent suppression achieved using 108 
WATERGATE and the spinlock in TOCSY experiment was attained by MLEV sequence.  109 
 110 
Determination of RNA-bound structure of the 7-mer peptide: 111 
Mixing time for NOESY was 400 ms and the same for TOCSY (with MLEV spinlock) 112 
experiment was 60 ms for transferred NOE experiments. The distance between two protons was 113 
determined under transferred NOE conditions. NOESY experiments were done at a final 114 
concentration of 450?M 7mer peptide with 15 ?M p383 RNA at 283K in 20mM deuterated Tris-115 
HCl buffer, pH 7 containing 100mM NaCl. The one-dimensional spectrum under these 116 
conditions is significantly broadened compared to free peptide without showing any new peaks 117 
indicating fast exchange conditions. The distance between two adjacent protons in the aromatic 118 
ring of a tyrosine residue, i.e., 2.48 Å was considered as the standard. It was used to calculate all 119 
other distances by comparing their peak volumes, respectively. However, the distance constraints 120 
were given in terms of strong (<3.5 Å), medium (3.5–4.5 Å), and weak (>4.5 Å) and may be 121 
considered somewhat of an overestimate due to transferred NOE conditions used. The maximum 122 
limit kept was 5.0 Å and the minimum 2.8 Å. The angle constraints were derived by direct 123 
measurements of scalar coupling constants from one-dimensional spectrum under conditions 124 
mentioned above and corresponding dihedral angles were derived from Karplus relationships. An 125 
upper and lower limit of ? 20o was used for angle constraints. The J-values were also cross-126 
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checked with those obtained from DQF-COSY and procedure of Kim and Prestegard (22). Total 127 
of 30 distance constraints and 6 ? angle constraints (Table 1) were used for structure 128 
determination. 129 
The angle and distance constraints, along with the complete protein sequence were fed into the 130 
software program DYANA to calculate the structures. Those with target function values were 131 
40.00 or lower (i.e. deviation from the inputs) were combined and energy was minimized by 132 
DISCOVER 3.0 in molecular modeler INSIGHT II version 2005 (Biosym/MSI) using the simple 133 
minimization algorithm. Then the structures were validated by RCSB validation server and the 134 
statistics were given in Table 2. 135 
 136 
Peptide synthesis and purification: 137 
The peptides LaR2C (KYKETDLLILFKDDYFAKKNEERK) corresponding to residue 174-197 138 
of the La protein, the mutant LaR2C (KYKATDLLILFKDDYFAKKNEERK) peptide and the 139 
non-specific La peptide (aa71-98, Ref 19) termed as La-Nsp (ALSKSKAELMEISEDKTK) were 140 
custom synthesized at Sigma Genosys, with 90% purity. The peptides were dissolved in 141 
nuclease/protease free water, and integrity was checked by gel-electrophoresis followed by silver 142 
stain analysis. 143 
All other smaller peptides (with or without 6XArg tag), were synthesized on a 0.1-mmol scale by 144 
solid-phase peptide synthesis strategy using Fmoc chemistry and Rink amide resin. Cleavage of 145 
the peptide from Rink amide resin and removal of all side chain-protecting groups were achieved 146 
in 95% trifluoroacetic acid solution. The crude peptides were purified by reversed-phase high-147 
performance liquid chromatography (RP–HPLC, Waters Associates) on a Waters C-18 column 148 
(µBondapak) with linear gradients of water/acetonitrile containing 0.1% trifluoroacetic acid. 149 
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Peptide masses and purity (>95%) were checked by positive ion mode ESI-MS (WATERS Inc., 150 
USA). 151 
 152 
Plasmids and cells: 153 
The construction of the plasmids pRSET-A La, pHCV383Luc monocistronic construct, and the 154 
bicistronic construct containing HCV IRES have been described earlier (29). The HCV 155 
monocistronic replicon construct pFKi383hygubiNS3-3’5.1 used in the study was a generous gift 156 
from Dr. R. Bartenschlager (26). The mutant La clones were generated by megapriming PCR 157 
method and cloned into pRSET-A expression vector. The mutants carried substitutions only at 158 
the respective aminoacid positions (P2 or P4 or P15 or P21/22), all other positions remained 159 
unaltered. Thus the changes were only on RRM (112-184), not in other RRMs. The PV 5’UTR 160 
or HCV IRES (18-383nt) were cloned upstream of luciferase reporter gene in pCDNA3.1 to 161 
generate pCDPVLuc or pCDHCV Luc monocistronic construct respectively. Additionally, the 162 
HCV IRES (18-383) or  HAV 5’UTR was cloned in between RLuc and FLuc reporter genes in 163 
pCDNA3.1 vector to generate the respective bicistronic constructs. 164 
Huh7 monolayer cells were grown in DMEM supplemented with 10% FBS and for the Huh7 165 
cells harboring HCV replicon were grown in DMEM with 10% FBS, 25?g /ml Hygromycin B 166 
(Calbiochem).         167 
 168 
Purification of wild-type and mutant La proteins:  169 
The wild-type and the mutant La proteins were over expressed in E. coli BL21 (DE3) cells and 170 
purified using nickel NTA agarose column as described earlier (29).  Briefly, the cultures were 171 
induced with 0.6mM IPTG for 4 hours at 370C. The crude extracts were mixed with Ni-NTA 172 
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agarose slurry (Qiagen) and kept for rocking at 4?C for 4 hours. The lysate was loaded onto a 173 
column, washed with 50 ml of wash buffer (50mM NaH2PO4, 300mM NaCl, 40mM imidazole) 174 
and the bound proteins were eluted with 500?l of elution buffer containing 500mM imidazole. 175 
The eluted proteins were dialyzed at 4?C for 6h in dialysis buffer (50mM Tris/pH7.4, 100mM 176 
KCl, 7mM ?-ME, 20% glycerol), aliquoted and stored in -70?C freezer. 177 
 178 
in vitro transcription and translation 179 
Radiolabeled mRNAs were transcribed in vitro using T7 RNA polymerase (Promega) and 180 
[?32P] UTP. The HCV-IRES (18-383nt) cloned in pcDNA3 vector was linearized with EcoRI, 181 
gel eluted and transcribed in vitro in presence of [?32P] UTP to generate the labeled HCV-IRES 182 
RNA as described previously(30). The HCV-IRES containing moncistronic construct (HCV 183 
luciferase) was linearized with XhoI to prepare HCV Luc RNA and the HCV bicistronic 184 
construct was linearized with PmeI to generate capped bicistronic RNA (Rluc-HCV IRES-Fluc 185 
in order) to use in the in vitro translation studies. The moncistronic construct, pCD Luc 186 
(containing luciferase gene in pCDNA3 backbone), was linearized downstream of luciferase 187 
gene with XhoI and the template was used to generate capped luciferase RNA by in vitro 188 
transcription in presence of cap analog using T7RNA polymerase. HAV bicistronic construct 189 
was linearized downstream of firefly luciferase and used as template for RNA synthesis as 190 
described earlier (30). The poly-linker sequence of pGEM-T-easy vector was linearized with 191 
SacI to generate the non-specific (Nsp) RNA. 192 
in vitro translation of the capped Luciferase mRNA, capped bicistronic RNAs or uncapped 193 
HCV Luciferase RNA was carried out in micrococcal nuclease treated rabbit reticulocyte lysate 194 
(RRL, Promega Corporation, WI, and USA) as described previously (30).  195 
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UV cross-linking experiment:  196 
The purified proteins or the synthetic peptides were incubated with ~75 fmoles of either 197 
[32P]labeled HCV IRES RNA or the Nsp RNA at 370C for 15 minutes containing RNA binding 198 
buffer (5mM HEPES pH 7.6, 25mM KCl, 2mM MgCl2, 3.8% Glycerol, 2mM DTT, 0.1mM 199 
EDTA and 5?g tRNA) in a reaction volume 15?l;  the complex was then subjected for UV 200 
induced cross-linking as described earlier (29).The entire reaction mixture  were then denatured 201 
followed by SDS-10% PAGE (for protein) or Tris-Tricine 17%PAGE (for peptide) and analyzed 202 
by phosphorimaging.  203 
 204 
Filter binding assay:  205 
The [?32P] labeled HCV IRES RNA, or the Nsp RNA was incubated with the wild-type La or 206 
the mutant La proteins or the peptides at 30?C for 15 minutes in RNA binding buffer (containing 207 
5mM HEPES pH 7.6, 25mM KCl, 2mM MgCl2, 3.8% Glycerol, 2mM DTT and 0.1mM EDTA). 208 
The reaction mixtures were loaded onto nitrocellulose filters equilibrated with the 2ml RNA 209 
binding buffer. The filters were then washed four times with 1ml of binding buffer and air-dried. 210 
The counts retained were measured in liquid scintillation counter. The graph was plotted with 211 
protein or peptide concentration (?M) on x-axis and the percentage of bound RNA as the 212 
percentage of counts retained, on the y-axis. 213 
 214 
Real time RT-PCR – RNA isolated from the from peptide treated and untreated replicon cells 215 
were reverse transcribed with HCV 5’primer using AMV RT (Promega) for the amplification of 216 
negative strand of HCV RNA .  For real–time PCR analysis, the cDNA was used for PCR 217 
amplification using a Real-time assay mix (Finnzymes) as per manufacturer’s instruction and the 218 
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data was analyzed by ABI-Prism’s Real time PCR machine. Actin was used as an internal 219 
control for the above reactions. 220 
 221 
Fluorescence microscopy- Huh7 monolayer cells were grown on coverslip upto 70% 222 
confluency.  Before addition of the peptide, cells were washed with PBS twice and then 223 
incubated with 1?M of Fluorescein labeled peptide (dissolve in DMEM) for 3 hours. After 224 
extensive wash with PBS, cells were fixed with 3.7% formaldehyde for 30min at room 225 
temperature, followed by washing with PBS for two times. Cells were observed under 226 
Fluorescence microscope. 227 
 228 
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RESULTS: 229 
NMR spectroscopy of the HCV IRES RNA bound peptide complex:  230 
Identification of amino acid residues important for recognition of RNA can be performed 231 
by NMR spectroscopy. In this case, since the RNA is relatively large (18-383 nt of HCV IRES), 232 
obtaining the full structure of the RNA-peptide complex (1:1) would have been extremely 233 
difficult. Alternatively, NMR spectrum of the 24-mer peptide was studied, which was relatively 234 
simple, in the absence and presence of sub-stoichiometric amount of RNA. It was assumed that 235 
under fast exchange condition, the chemical shifts of peptide protons in the absence of RNA will 236 
be average of free and bound species (intensity of RNA protons will be insignificant due to sub-237 
stoichiometric presence and broader line-width). Thus, comparison of peptide chemical shifts in 238 
the presence of RNA with that of the free peptide is expected to shed light on the residues that 239 
may be involved in recognition. 240 
‘Total Correlation Spectroscopy’ (TOCSY) provides connectivity between all adjacent 241 
protons (three-bond connectivity) within an amino acid unit and hence a fingerprint for the type 242 
of amino acid. Figure 1A shows the TOCSY spectrum of the region that connects NH 243 
(approximately 7.5 to 9.5 ppm) with ?H and other side-chain protons. Out of the expected 23 244 
NH protons, 18-19 could be resolved. When sub-stoichiometric amount of RNA was added, 245 
significant shift of many protons (but not all), were observed. This perhaps indicated either an 246 
extensive peptide-RNA interface or a folding of the peptide coupled to RNA binding. 247 
Determination of the bound conformation of the peptide and the whole interface is beyond the 248 
scope of this work and we have focused on identifying at least one region that may be involved 249 
in recognition. This will allow us to mutate that residue in the whole protein and validate that the 250 
peptide is a good model for studying protein-RNA interaction. 251 
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Among other shifted residues in the TOCSY spectra, one residue at 8.27 ppm shows significant 252 
shift upon complex formation (Figure 1; indicated by an arrow). Chemical shifts and 253 
connectivity patterns  indicate that this residue is a glutamic acid (no glutamine is present in the 254 
peptide). There is only one threonine (position 5) in the peptide. Threonine ?, ? and methyl 255 
protons have very characteristic chemical shifts and can be identified easily. Figure 1B shows the 256 
position of T178. T178 is connected to the shifted glutamic acid (E177) by NOE (Figure 1C) 257 
indicating that the glutamic acid at 8.27 ppm is E177. Thus, at least E177 is likely to be involved 258 
in recognition of HCV IRES RNA. Additionally, significant shifts were observed corresponding 259 
to Y175 (Tyr) at the N terminus and also Y188 (Tyr) and K192-N193-E194 positions at the C 260 
terminus of the LaR2C peptide. 261 
 262 
Effect of point mutation within the LaR2C region of La protein on HCV IRES binding: 263 
  As mentioned above, the chemical shift perturbation can be due to direct interaction or 264 
indirect coupled folding events. In order to investigate whether the above amino acid residues of 265 
La protein are actually involved in recognition of HCV IRES RNA, we have generated 266 
corresponding point mutations in the full-length protein using site-directed mutagenesis (Fig 267 
2A). The RNA binding activities of the mutant La proteins were tested and compared with that 268 
of Wt-La protein by UV-crosslinking assay using [32P] labeled HCV IRES RNA. The results 269 
showed that mutations at the La175Y-A and La177E-A (corresponding to N-terminus P2 and P4 270 
positions of LaR2C peptide) mostly affected the HCV IRES binding. Whereas, mutations at 271 
La188 Y-A  and La 194 E-A-195 E-A  (corresponding to C terminus, positions P15 and P21/22) 272 
didn’t significantly alter the RNA binding ability of La protein (Fig 2B).  273 
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Additionally, filter binding assay was performed using [32P] labeled HCV IRES RNA and 274 
increasing concentration of purified recombinant proteins (Wt-La or the mutants). Considering 275 
the mid point of transition, it appeared that the mutation at the P4 residue significantly affected 276 
the RNA binding ability of La protein. Mutation at P2 residue also showed decrease in RNA 277 
binding ability, but to some extent only. However mutation at P15 or P21/22 didn’t alter the 278 
binding ability of La protein (Fig 2C). As expected, a non specific RNA probe didn’t show 279 
considerable binding with the wt-La protein in the same filter-binding assay. 280 
Earlier, we have shown that LaR2C peptide can effectively compete with full-length La protein 281 
for binding near the iAUG within HCV IRES RNA (30). Here, in the competition UV-282 
crosslinking experiment we have observed that the full-length Wt-La protein can also compete 283 
out binding of LaR2C with the HCV IRES RNA (Fig 2D). However, the mutant P4-La protein 284 
failed to compete the binding of LaR2C peptide significantly with the HCV IRES RNA (Fig 2D). 285 
The result suggests, that the domain of La protein encompassing the amino acid P4 (La177E-A) 286 
might be involved in making contact with the HCV IRES RNA near initiator AUG where LaR2C 287 
peptide also binds. However, binding of La protein to other sites within HCV IRES RNA might 288 
not be affected as much with the above mutation. 289 
 290 
Effect of mutation in the LaR2C peptide on RNA binding and translation 291 
 292 
To further investigate the role of N terminal amino acids in the peptide activity we have 293 
generated a mutant LaR2C peptide where E177 was changed from Glutamic acid to Alanine (Fig 294 
3A). The RNA binding ability of the wild type and mutant peptide were tested by UV-cross-295 
linking assay. For this purpose [? 32P] labeled HCV IRES RNA was UV cross-linked with 296 
increasing concentration of either wt LaR2C or the mutant LaR2C or a non-specific La peptide. 297 
Result showed that the mutation at P4 (La177E-A) did affect the RNA binding ability of the 298 
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mutant peptide (Fig 3A). The non specific peptide (Nsp) didn’t show any RNA binding activity 299 
(Fig 3A). To further confirm the RNA binding ability of the peptides, filter binding assay was 300 
performed using increasing concentration of wild-type and mutant peptide and ? 32P labeled 301 
HCV IRES RNA. The results showed reduced level of saturation for the mutant peptide-RNA 302 
complex compared to the wt LaR2C peptide, suggesting critical role of the P4 residue in the 303 
activity of the LaR2C peptide (data not shown).  304 
 305 
Interestingly, results from similar filter binding assay suggest that the deletion of N-306 
terminal amino acids almost abrogated the RNA binding activity of the peptide (?LaR2C-C14), 307 
whereas retention of only 14 amino acids in the N terminus (?LaR2C-N14) appeared to be 308 
sufficient for significant RNA binding activity (Fig 3B). 309 
Additionally, the effect of mutation in the peptide was tested in the in vitro translation 310 
assays in Rabbit Reticulocyte Lysate (RRL) using uncapped monocistronic RNA containing 311 
HCV IRES upstream of Firefly luciferase gene. Results showed significant decrease in HCV 312 
IRES mediated translation of HCV Luc RNA in presence increasing concentration (30?M -50%, 313 
and 60?M-70% inhibition) of Wt LaR2C peptide. However similar concentration of mutant 314 
peptide failed to inhibit the HCV IRES function significantly (Fig 3C). Also, it appears that the C 315 
terminal truncated peptide ?LaR2C-N14 retained the translation inhibitory activity as compared 316 
to wild-type peptide control. However, deletion of N terminal amino acids (?LaR2C-C14) 317 
resulted in abrogation of the translation inhibitory activity (Fig 3C). 318 
 319 
Characterization of conformation of the N-terminal seven residue peptide: 320 
 The N-terminal part of the LaR2C (174-196aa) has been shown to constitute ?4-sheet and 321 
?4’ strand of RRM (101-200) (1). Interestingly, the residues of the peptide responsible for RNA 322 
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recognition were found to map to a turn in the context of RRM (112-184) NMR structure. Based 323 
on earlier NMR structure information (PDB ID 1S79), when the LaR2C peptide was modeled, 324 
these critical N-terminal amino acids were found to be located in a similar turn that appears to be 325 
exposed for RNA binding (Fig 4A). 326 
 Since, the RRM (112-184) structural model suggests that the N-terminal seven residues 327 
completely cover the turn that sticks out of the globular structure of the domain (Fig 4A) we 328 
were interested to investigate the structure and function of the 7 residue peptide. 329 
 The HCV IRES RNA bound structure of LaR2C-N7 structure was determined by NMR 330 
spectroscopy. Under bound conditions, the peptide gave several new NOEs and change of value 331 
of J for several amide protons in addition to significant line broadening (data not shown). This 332 
indicates that conformational parameters derived from this experiment indeed reflect the bound 333 
form. The sequence KETD forms a ?-turn as distance between C? atoms of K and D is less than 334 
7Å (Fig 4B). However, the Ramachandran angles do not fall within any defined turn category. 335 
The KETD sequence in the RRM (112-184) structure is also a ?-turn but the conformational 336 
parameters do not fall strictly into any well-defined category (Fig 4C). Although, the structures 337 
in two contexts are similar, there are noticeable differences in Ramachandran angles. Thus, there 338 
could be significant remodeling of the structure upon binding of La to the RNA (Fig 4D). 339 
 340 
The smaller peptide (LaR2C-N7) inhibits HCV IRES mediated translation in vitro  341 
After determining the preference for beta turn conformation in the N-terminal 7-residues 342 
we were interested to investigate whether the 7mer peptide comprising of these amino acids will 343 
also inhibit HCV IRES mediated translation. For this purpose we have used monocistronic RNA 344 
containing HCV IRES upstream of reporter luciferase gene in the in vitro translation assays in 345 
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presence or absence of increasing concentration of LaR2C-N7 peptide. Interestingly, the smaller 346 
peptide (LaR2C-N7) also showed translation inhibitory activity which is only slightly weaker 347 
than the 24-mer peptide (Fig 5A). However, mutation at the P4 position of the LaR2C-N7 348 
completely abrogated its translation inhibitory activity (Fig 5B). Interestingly, the peptide 349 
LaR2C-N7 didn’t show significant inhibition of capped-Luciferase RNA (representing cap-350 
dependent translation) suggesting the specificity of the inhibition (Fig 5C). Also, LaR2C-N7 351 
showed selective inhibition of HCV IRES mediated translation in the context of HCV bicistronic 352 
RNA (Fig 5D). Further, the LaR2C-N7 peptide failed to inhibit IRES mediated translation of 353 
hepatitis A virus, but showed significant inhibition of Polio virus IRES function at higher 354 
concentration (Fig 5E). 355 
 More importantly, addition of increasing concentration purified wt-La protein showed 356 
significant rescue of the suppressive effect of LaR2C-N7 (Fig 5F). However similar 357 
concentration of BSA protein was not able to rescue the inhibition. Addition of increasing 358 
concentration of recombinant La protein (25ng, and 50ng) in the reaction (in absence of peptide) 359 
showed dose dependent stimulation in HCV IRES mediated translation (data not shown) as 360 
observed earlier (29). The result reinforces the idea that the LaR2C-N7 peptide mediated 361 
inhibition of translation could be due to competition with the endogenous La protein. Taken 362 
together the results suggest that the turn at the N terminus of the LaR2C peptide could be critical 363 
for its RNA binding as well as translation inhibitory activity. 364 
 365 
The arginine-tagged LaR2C-N7 peptide inhibits HCV IRES function in vivo 366 
 To investigate whether the LaR2C-N7 peptide would be equally effective in inhibiting 367 
HCV IRES mediated translation in vivo in Huh7 cells; we have explored delivery of the peptides 368 
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inside the cells with the help of hexa-arginine fusion tag. Arginine-tagged peptide has the 369 
property to internalize into mammalian cells when supplied exogenously into the medium (13). 370 
The RNA binding ability of the arginine tagged LaR2C-N7 peptide was demonstrated by UV 371 
cross-linking experiment using [32P] labeled HCV IRES RNA. The mutant mLaR2CN7-4 372 
(arginine-tagged) peptide didn’t show appreciable RNA binding activity. A non-specific RNA 373 
probe was also used as negative control in the experiment (Fig 6A). 374 
 To investigate the internalization of the arginine–tagged peptides, we have used 375 
fluorescein labeled hexa arginine-tagged peptides and found that both the peptides are 376 
internalized inside Huh7 cells (Fig 6B).   To investigate the effect of these peptides on HCV 377 
IRES function inside the cells, we have used these arginine-tagged peptides in Huh7 cells. Huh7 378 
monolayer cells were first transfected with the pcDNA3-HCV bicistronic construct and 379 
incubated for 3 hours, washed and layered with medium containing 2?M of Arg-LaR2C-N7 380 
peptide and incubated further for either 4 hours or 6 hours. Similarly, as a negative control, 381 
another set of dishes was layered with mutant peptides (Arg-mLaR2C-N7-4). After incubation 382 
with the peptide, the cells were washed and then lysed and the luciferase activities (Fluc and 383 
Rluc) were measured. The relative luciferase activities were represented where Rluc represents 384 
cap dependent translation and Fluc represents HCV IRES mediated translation. The results 385 
showed significant decrease (inhibition up to 70%) in the HCV IRES mediated translation over 386 
the control, when cells were incubated with Arg-LaR2C-N7 peptide. However, the mutant (Arg-387 
LaR2C-N7-4) did not show appreciable inhibitory effect (Figure 6C and 6D). The absolute levels 388 
of RLuc and FLuc activities of a representative experiment are presented in the table (Fig 389 
6E).Taken together, these results indicated that LaR2C-N7 does compete with the interaction of 390 
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cellular La protein to HCV IRES RNA and exert a dominant negative effect to inhibit HCV 391 
IRES mediated translation in vivo.   392 
 Additionally, to test whether this peptide would inhibit HCV replication as well, we have 393 
treated Huh7 cells harboring HCV monocistronic replicon (26) with either Wt (Arg-LaR2CN7) 394 
or mutant (Arg-mLaR2C-N7-4) peptide for 24 hours. The peptides (4?M) were added twice with 395 
12 hours intervals of time. As the measure of negative strand synthesis indicates replication of 396 
HCV RNA (4), we have quantitated it by real time RT-PCR.  The results showed almost 50% 397 
decrease in levels of HCV negative strand RNAs compared to the untreated cells when 4?M of 398 
ArgLaR2C-N7 peptide was used (Fig 6F). However, the mutant peptide (Arg-mLaR2C-N7-4) 399 
didn’t show appreciable decrease in negative strand synthesis (Fig 6F). At lower concentration of 400 
the peptide (2?M) the inhibition was around 30% and at higher concentration (10?M), 401 
considerable increase in the inhibitory activity was observed (data not shown).  402 
 Taken together, the results provide the ‘proof of concept’ that the peptide LaR2C-N7 403 
might be effective against HCV IRES function and consequently inhibit replication of HCV 404 
RNA in Huh7 cells. 405 
 406 
DISCUSSION: 407 
Hepatitis C is a major public health problem with limited established therapeutic options. 408 
Most common established therapy is interferon ?, which is not effective in majority of the cases. 409 
Newer experimental therapies include nucleoside analogs, protease inhibitors and polymerase 410 
inhibitors, but there is a growing need for agents that are directed against new targets (35).  411 
Human La protein plays an important role in HCV infection. Earlier studies indicated that 412 
for HCV IRES RNA, which lacks 3’UUUOH,   several sub-domains of La protein contributes to 413 
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RNA recognition. The central RRM (112-184) binds strongly to HCV IRES in the context of 414 
iAUG, whereas the C-terminal RRM (230-300) and the hydrophobic domain have also been 415 
shown to contribute to HCV IRES binding perhaps at other sites (2, 6, 29, 31). Earlier, La motif 416 
was shown to indirectly influence the RNA binding ability of the La protein via other RRMs 417 
(19). However, we have demonstrated that RRM (112-184) of La protein directly binds to HCV 418 
IRES RNA at the GCAC near iAUG (29-31). We have also demonstrated that LaR2C peptide 419 
(corresponding to 174-196 aa) interacts with the GCAC near iAUG in the SLIV region and act in 420 
a dominant negative manner by competing with the endogenous La protein binding at this site 421 
(30, 31).  Thus, La-HCV IRES interaction could be a potential target for drug design. In fact, 422 
earlier Izumi et al also reported a short peptide LAP (aa11-28) derived from La motif, which 423 
could selectively inhibit IRES mediated translation of hepatitis C and poliovirus (19). 424 
 Our results are consistent with the earlier study by Izumi et al (19) that a single point 425 
mutation in the La-motif of the full-length La protein can completely abrogate the RNA binding 426 
activity. Both the studies indicate that perhaps the secondary structure and the tertiary 427 
interactions between the domains influence La protein folding which might contribute to RNA 428 
binding. Thus point mutation at any of the hot spots (La motif or RRM) could have drastic 429 
consequence in the La protein structure and its RNA binding ability.  430 
 The inhibitory activity of the peptides may not be attributed to their RNA-binding 431 
ability alone. In fact in our earlier publication (30) we have mentioned that, in addition to HCV 432 
RNA binding, the LaR2C peptide might also interfere with the binding of some other cellular 433 
protein factors to HCV IRES RNA and thus the inhibitory effect of the peptide could be the 434 
combination of both effects. It is possible that the mutation at P4 in the LaR2C peptide might 435 
have affected both the possibilities and hence have drastically reduced the inhibitory activity. It 436 
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is worth mentioning that the LAP peptide (as reported earlier) didn’t show HCV IRES RNA 437 
binding, but still could inhibit the translation effectively (19).  438 
La protein have been shown to interact with the HCV 3’UTR and influence the viral 439 
RNA replication (8). It would be interesting to investigate whether LaR2C peptide or its smaller 440 
derivative (LaR2C-N7) dislodges La binding to HCV 3’UTR as well. In that case the inhibitory 441 
effect of the peptide on HCV RNA replication should have been more pronounced. However, at 442 
this point we can’t comment on whether the 50% inhibition of HCV RNA replication achieved 443 
by LaR2C-N7 peptide (4?M) is mere consequence of translation inhibition. Future experiments 444 
would be directed to address this issue using higher concentration of the peptide and also test the 445 
efficacy of this peptide in protecting cells from HCV infection in cell culture model. 446 
Although, a large peptide has been used as a drug in other viruses, e.g. against HIV (T-447 
20), in general the potential of drug development increases sharply as the molecular weight of 448 
the peptide decreases. In this study we have demonstrated that a small 7-mer peptide (hexa-449 
arginine tagged) corresponding to an exposed turn can significantly inhibit HCV IRES mediated 450 
translation in cell culture at even significantly lower concentration (2?M) than required for 451 
inhibition of translation in vitro. The hexa-arginine tagged 7-mer peptide is also capable of 452 
inhibiting HCV RNA replication. The fact that the effect of the peptide (at 4?M concentration) 453 
on HCV replication is only 50% could be due to its relative instability during long incubation. 454 
But designing peptidomimetics through mimicking of this turn might improve both the affinity 455 
and in vivo stability (Bioavailability).  456 
The bound structure of the peptide inferred from transferred NOE experiments suggests it 457 
to be a ?-turn, but falling into no defined category (37). The NMR structure of the un-liganded 458 
domain indicates this conformation to be a ?-turn as well. However, the Ramachandran angles of 459 
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i+1 and i+2 residues are different from the prescribed values of any type of ?-turn (Hutchinson 460 
and Thornton 1988). Even though the domain structure and the bound peptide structure are both 461 
?-turns and falling into any defined category, they are themselves different. This suggests 462 
conformational change of the turn upon binding to target RNA. Thus, stabilization of the bound 463 
?-turn conformation in a peptidomimetic by suitable  residues may enhance binding.   464 
Specificity is a crucial issue in designing peptidomimetics as well as other therapeutic 465 
entities. Lack of inhibition of IRES function with E4 mutations (mLaR2C-N7-4) strongly 466 
suggests highly specific mode of inhibition. In addition, the fact that the LaR2C-N7 peptide did 467 
not inhibit HAV IRES suggests the specificity of its inhibitory activity. It is possible that La 468 
protein is not as critical for HAV-IRES function. On the other hand, La protein has been shown 469 
to interact and enhance IRES mediated translation of Poliovirus RNA. However, LaR2C-N7 470 
peptide was not as effective against Polio virus IRES mediated translation again indicating high 471 
degree of selectivity. Domains other than RRM (101-200) have been attributed for this 472 
stimulatory function in polio virus (6). Also, the LaR2C-N7 peptide can selectively inhibit HCV 473 
IRES mediated translation in vivo at 2?M concentration without affecting cap-dependent 474 
translation, suggesting specificity of the approach.  475 
One notable point here is that in the in vitro translation assays approximately 60?M 476 
concentration of 7mer peptide was necessary to achieve around 70% inhibition. However, the 477 
hexa-arginine tagged 7mer peptide was found to be more effective and similar levels of 478 
inhibition were achieved at much lower concentration (5-10??) (data not shown). Even in the in 479 
vivo assay 2-4?M hexa-arginine tagged peptide was sufficient to achieve 50% inhibition. It is 480 
possible that the hexa-arginine residues might have played some unintended positive roles by 481 
contributing in the net positive charge of the peptide and thus enhanced its RNA binding ability 482 
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thereby increasing the inhibitory activity as well. Also, in the in vivo situation, in the context of 483 
properly folded HCV IRES RNA in presence of other trans acting factors, the inhibitor could be 484 
more effective.  485 
Field of therapeutic peptide analogs is at its infancy. Many of the problems associated 486 
with use of therapeutic peptides are gradually being solved. In fact a number of peptidomimetics 487 
are currently being tried as antiviral agents (9, 17). One of the best approaches in design of 488 
effective peptidomimetic is to replace naturally occurring amino acids with unnatural amino 489 
acids that stabilize the interacting conformation guided by structure of the peptide. This not only 490 
reduces the entropy cost of binding to the receptor (disorder to order), but also stabilize the small 491 
peptides from proteolysis and degradation (3). Design of peptidomimetic inhibitor such as 492 
BILIN–2061 against HCV protease was possible on the basis of structural relationship studies 493 
(SAR), availability of crystal structure of the protease, replacement of the natural amino acids etc 494 
(33, 39). Availability of the structure of this small peptide will be helpful in developing more 495 
stable peptidomimetic with higher affinity for HCV IRES so that it could effectively inhibit 496 
IRES dependent translation at much lesser concentration while increasing the bioavailability and 497 
solving the stability issues.  498 
 499 
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FIGURE LEGENDS: 618 
Figure 1: NMR analysis of HCV IRES RNA bound peptide: 619 
Panel A: Overlay of two TOCSY spectra, pink colored one is for the LaR2C peptide without 620 
RNA and the green colored one is for the La derived peptide with HCV-IRES RNA. The arrow 621 
indicates the shifting of the E177 peaks after addition of HCV-IRES RNA. All the spectra in this 622 
figure were recorded in a Bruker DRX-500 NMR spectrometer. The experimental details are 623 
given in the Materials and Methods section.  624 
Panel B: TOCSY spectrum of the LaR2C with spin system identification of two amino acid 625 
residues, labeled with their corresponding one-letter symbols. The subscripts indicate the amino 626 
acid position in the peptide.  627 
Panel C: Overlay of TOCSY (red) and NOESY (blue) spectra of the LaR2C and demonstration 628 
of TOCSY-NOESY connectivity between T178 and E177. The boxes identify the location of the 629 
NH-?H TOCSY cross peaks for the residues E177 (down field) and T178 (up field). 630 
 631 
Figure 2: Effect of point mutation in La protein on HCV IRES binding 632 
Panel A: Schematic representation of the domain organization of human La protein. The residues 633 
mutated in full-length La protein (between 174-197aa) with their corresponding positions with in 634 
24-mer LaR2C peptide is indicated.  635 
Panel B: UV cross-linking analysis. [?32 P] UTP labeled HCV IRES RNA (~75fmole) was UV 636 
cross-linked with increasing concentration (150, 300ng) of either wt La protein or the mutants 637 
(as indicated on top of the lanes). The protein-nucleotide complex was resolved in SDS-10% 638 
PAGE followed by phosphor imaging analysis. The position of La protein (p52) is indicated. The 639 
band intensities corresponding to La were quantified by densitometry. The numbers below the 640 
lanes 3, 5, 7 and 9 represents the relative intensities taking lane 1 (150ng protein) as control, 641 
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whereas the numbers (in bold) below lane 4, 6, 8 and10 represents the relative intensities taking 642 
lane 2 (300ng protein) as control. 643 
Panel C: Filter-binding assay: [?32P] labeled HCV IRES RNA was bound to increasing 644 
concentrations of either wild-type La, or the mutant La proteins (as indicated). Additionally, 645 
[?32P] labeled nonspecific RNA was also used along with the wild-type La protein. The amount 646 
of bound RNA was determined by binding to the nitrocellulose filters. The percentage of bound 647 
RNA was plotted against the protein concentration (?M).  648 
Panel D: Competition UV-cross linking: [?32P] UTP labeled HCV IRES RNA was pre-incubated 649 
with LaR2C peptide followed by addition of either wt-La protein (lanes 2-3) or mutant La 650 
protein (P4, lanes 4-5) in the reaction mixture for competition. The UV cross-linked complex 651 
was treated with RNase and resolved by SDS 15% Tris-Tricine gel. The relative position of the 652 
band corresponding to LaR2C peptide is indicated with an arrow. The numbers below the lanes 653 
represent the relative band intensities taking lane 1 as control. 654 
 655 
Figure 3: Effect of P4 point mutation in LaR2C peptide activity 656 
Panel A: Schematic representation of the peptide used in the UV cross-linking analysis. The 657 
residue mutated in mutant LaR2C peptide is indicated in italics. [?32P] UTP labeled HCV IRES 658 
RNA (~75fmole) was UV cross-linked with increasing concentration (30?M, 60?M) of LaR2C, 659 
mLaR2C and La-NSP. The peptide-nucleotide complex was resolved in 15% Tris-tricine PAGE 660 
followed by phosphor imaging analysis. The band intensities were quantified by densitometry. 661 
The numbers below the lanes represent the intensities taking lane 1 (no peptide) as control. 662 
 663 
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Panel B: Filter-binding assay: [32P] labeled HCV IRES RNA was bound to increasing 664 
concentrations of either wild-type LaR2C peptide or mutant  peptides as indicated. The amount 665 
of bound RNA was determined by binding to the nitrocellulose filters. The percentage of bound 666 
RNA was graphically represented against the peptide concentration (?M).  667 
Panel C: Effect on HCV IRES mediated translation in vitro: One microgram of uncapped HCV- 668 
IRES-Luc RNA was translated in RRL in absence (lane1) or in presence of increasing 669 
concentration (30 and 60 ?M) of either Wt LaR2C or  mutant peptides (as indicated). The 670 
relative FLuc activities were represented as a percentage of the control reaction (expressed as 671 
100%).  672 
 673 
Figure 4: Structural characterization of the LaR2C-N7 peptide 674 
 675 
Panel A: Structural model of LaR2C in the context of structural model of RRM (101-200) of La 676 
protein (PDB ID 1S79). The helix regions are colored pink, ?-sheets are colored yellow and turns 677 
and random coils are colored grey. The wtLaR2C-N7 sequence lies in the grey region (174 to 678 
180 AA residues). The glutamic acid (177) is colored blue, threonine (178) is colored green and 679 
aspartic acid (179) is colored black.  680 
Panel B: Superimposition of best 16 structures (backbone) of 7-mer peptide (residuo174-180) 681 
under RNA bound conditions simulated using DYANA (Version 1.5. Peter Guentert & Kurt 682 
Wuthrich, Zurich, Switzerland). The amino acid residues are represented by three letter code and 683 
numbered corresponding to their position in RRM (101-200).  684 
Panel C: Backbone structure of RNA bound LaR2C-N7.  685 
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Panel D: 16 superimposed structures from the same region of RRM (101-200) structure for 686 
comparison. The amino acid residues are represented by three letter code and numbered from 687 
amino terminus starting from 174. 688 
 689 
Figure 5: Effect of LaR2C-N7 on HCV IRES-mediated translation in vitro 690 
 691 
Panel A and B: Above the panels, schematic representation of the wild-type 7mer peptide 692 
(LaR2C-N7) or the mutant 7mer peptide along with the 24-mer wild-type LaR2C peptide. The 693 
residue mutated is indicated in italics. One microgram of HCV IRES-Luc monocistronic RNA 694 
was translated in rabbit reticulocyte lysate (RRL) in absence or presence of increasing 695 
concentration (15, 30 and 60?M) of either the wtLaR2C-N7 or the mutant peptide mLaR2C-N7-696 
4. Respective luciferase activities were measured and plotted against different peptide 697 
concentration. The relative FLuc activities were represented as a percentage of the control 698 
reaction (expressed as 100%). Results represent an average of three independent experiments.  699 
Panel C: Similarly, one microgram of capped Luciferase RNA was translated in RRL in absence 700 
or presence of increasing concentration (15, 30, 60?M) of LaR2C–N7 peptide and luciferase 701 
activities were plotted against different concentration of the wtLaR2C-N7 peptide. The relative 702 
FLuc activities were represented as a percentage of the control reaction (expressed as 100%). 703 
Results represent an average of three independent experiments. 704 
Panel D: One microgram of capped bicistronic RNA was translated in RRL in absence or 705 
presence of increasing concentration (15, 30, 60?M) of LaR2C–N7 peptide and luciferase 706 
activities were plotted against different concentration of the wtLaR2C-N7 peptide. The relative 707 
RLuc and FLuc activities were represented as a percentage of the respective control reactions 708 
(expressed as 100%). Results represent an average of three independent experiments. 709 
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Panel E: 1µg of either PV–Luciferase monocistronic RNA or capped HAV-bicistronic RNA 710 
(containing Rluc-HAV-Fluc in order) translated in absence (lane 1) and presence of increasing 711 
concentrations (15, 30, 60µM) of LaR2C-N7 peptide. The translation of the firefly luciferase 712 
activities were measured and plotted against the peptide concentration for the respective 713 
construct as indicated. The relative FLuc activities were represented as a percentage of the 714 
control reaction (expressed as 100%). Results represent an average of three independent 715 
experiments. 716 
Panel F: One microgram of HCV IRES-Luc monocistronic RNA was translated in rabbit 717 
reticulocyte lysate (RRL) in absence or presence of wtLaR2C-N7 (40µM). Increasing 718 
concentrations (25ng, 50ng) of purified wild-type La protein or BSA (50ng) was added to the 719 
reactions as indicated below the lanes. Respective luciferase activities were measured and plotted 720 
in the graph. The relative FLuc activities were represented as a percentage of the control reaction 721 
(expressed as 100%). Results represent an average of three independent experiments.  722 
Figure 6: Effect of arginine-tagged LaR2C-N7 on HCV IRES function in Huh7 cells 723 
Panel A: UV cross linking:  Increasing concentration (2?M and 4?M) of hexa-arginine tagged 724 
peptides, Wt ArgLaR2C-N7 or the mutant Arg-mLaR2C-N7-4 was UV cross-linked with [?32P] 725 
UTP labeled HCV IRES RNA or a non-specific RNA probe and analyzed in SDS-17% Tris-726 
Tricine gel analysis followed by phosphorimaging.  727 
Panel B: Fluorescein tagged hexa-arginine peptides (both wild-type and the mutant) were 728 
incubated with the Huh7 cells for 3 hours, extensively washed with PBS, followed by 729 
observation under a fluorescence microscope. Left panel is for Wt ArgLaR2C-N7 and right panel 730 
is mutant Arg- mLaR2C-N7-4 peptide. 731 
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Panel C and D: Huh7 monolayer cells were transfected with 2?g of HCV bicistronic DNA 732 
(containing Rluc-HCV IRES-Fluc in order). After 3 hours of transfection, cells were overlaid 733 
with 2?M of either Wt or mutant Arg-LaR2C-N7 peptide. Cells were harvested at different time 734 
points (as indicated), lysed and luciferase activities were measured using dual luciferase assay 735 
system. The Rluc (grey bar) and Fluc (white bar) activities were plotted as fold increase or 736 
decrease in presence of the peptide with respect to the corresponding control (in the absence of 737 
peptide) taken as 100.   738 
Panel E: Absolute values of RLuc and FLuc activities (in relative light units) of a representative 739 
experiment are presented in the table. 740 
Panel F: Schematic representation of the HCV monocistronic replicon RNA?? adopted from 741 
Michael et al, 2003 (Ref 26). Monolayer Huh7 cell harboring above replicon was overlaid with 742 
either Wt 7-mer (ArgLaR2C-N7) or mutant7-mer (Arg-mLaR2C-N7-4) peptide (4?M each), 743 
added twice at 0 and 12th  hour. RNA was isolated at 24th hour time point and subjected to cDNA 744 
synthesis.    HCV negative strand was detected using real time PCR. Data were normalized with 745 
actin control and negative strand synthesis was expressed as fold change compared to control 746 
cells (in absence of peptide). 747 A
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Figure 3
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Figure 4
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Figure 6
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Table 2: Structure Determination Statistics for wtLaR2C-N7
Ramachandran plot statistics (%)
Number of non-glycine and non-proline residues        7
Number of end-residues (excluding Gly and Pro)        2
Number of glycine residues (shown as triangles)         0
Number of proline residues                                           0
Total number of residues                                        7
Residues in most favored regions                                40.0% 
Residues in additional allowed regions                       60.0%
Residues in generously allowed regions                      0.0%
Residues in disallowed regions                                  0.0%
Deviation from idealized geometry
Bond lengths (Å)                                                0.015
Bond angles (°)                                                 1.9
RMSD from experimental restraints
NOE(Å)                                                          0.154
Dihedral angle restraints (°)                                   13.6
Atomic RMSD
Backbone (all residues)                                         0.33
Heavy atoms (all residues)                                      1.62
Table 1: Restraints for  wtLaR2C-N7 (residue 174-180) peptide  
structure calculation
Restraints for  wtLaR2C-N7 (residuo174-180) peptide  
structure calculation
Restraints                                                   no.
Total NOE distance restraints                    30
Short-range(<3.5A0)                                   4  
Medium-range(3.5-4.5A0)                         16
Long-range(>4.5A0)                                  10
Dihedral angle restraints                            6
Hydrogen bond restraints                            0
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